Genentech, Inc. Granted Patent for TDO2 Inhibitors

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12583858B2 to Genentech, Inc. This patent covers inhibitors of cellularly expressed TD02, which are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing the effectiveness of anti-cancer treatments. The patent application was filed on October 12, 2020, and the grant is effective March 24, 2026.

This patent grant signifies a new intellectual property right for Genentech, Inc. regarding their TDO2 inhibitor technology. While not imposing direct compliance obligations on other entities, it establishes exclusive rights that may impact future research, development, and commercialization efforts in this therapeutic area. Companies operating in the oncology and immunology space should be aware of this patent's scope to avoid potential infringement.

Source document (simplified)

← USPTO Patent Grants

TDO2 inhibitors

Grant US12583858B2 Kind: B2 Mar 24, 2026

Assignee

Genentech, Inc.

Inventors

Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers

Abstract

Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.